The decision is based on data from a Phase 3 clinical trial called OUtMATCH.

Friday, February 16, 2024 NIAID Trial Data Underpins FDA Approval of Omalizumab for Food Allergy Credit: Adobe Stock NIAID-supported research underpins today's Food and Drug Administration decision to approve the monoclonal antibody omalizumab (Xolair) for people with food allergies. The decision is based on interim data from a Phase 3 clinical trial called OUtMATCH. Detailed final results from the first stage of the trial will be presented during a late-breaking symposium at the American Academy of Allergy, Asthma & Immunology Annual Meeting on Sunday, Feb. 25 at 1:45 pm ET. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107